Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.

Neurology · 2018 · PMC5902787 · PMID 29661905

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

17 In a larger (n = 125) phase III study of patients with an MG-ADL total score ≥6 who had previously failed treatment, the primary endpoint, change in MG-ADL, did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.